NeoDynamics: Wrap up from latest event with CEO Anna Eriksrud
NeoDynamics CEO Anna Eriksrud throughly presented the Full Year 2023 report and latest news after closing of the year. Due to the dire financial situation end last year, NeoDynamics introduced a cost reduction plan. The CEO expect an impact from March 2024 and onwards and full impact 2nd. half of 2024. NeoDynamics have secured short term financing of SEK 10 mio. through a bridge loan before Christmas 2023, and announced a rights issue of gross SEK 25 mio. in January 2024, net proceeds used for commercialization and marketing of NeoNavia™ in Europe and US. In connection with the rights issue the company decided to do a reverse split.
NeoDynamics has a very good dialogue with doctors and clinicians at tier 1 hospitals i US and Europe, but still waiting for commercial proof-of-concept in US. This is due to procurement and compliance dragging out on the NeoNavia system. Both the system and especially the Flexipulse needle is new innovations in the market and the long process is not an unique situation. All needles are ready for delivery to all clients in all markets and KOL (Key Opinion Leaders) have been a great help to the company and with very good feedback on the NeoNavia™ system. In Europe the company are currently working with 18 medical centres in UK and 23 medical centres in the DACH region. So far, they have been testing our biopsy system and needles in pilot studies and are now in the process of making decisions to buy own base units for future use. During the trial period, the centres have paid for needles but have rented the base unit and driver.
Watch the interview here: NeoDynamics Full Year 2023 event
Disclaimer: HC Andersen Capital receives payment from NeoDynamics for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 07:45 AM 19-02-2024.
Neodynamics
Neodynamics är verksamt inom medicinteknik. Idag är verksamheten inriktad mot att utveckla och kommersialisera produkter för behandling av kritiska sjukdomar. Via egenutvecklad mikropulsteknologi erbjuder bolaget precisionsbehandlingar mot bland annat cancer. Lösningarna används främst vid behandling avb bröstcancer hos kvinnor. Huvudkontoret ligger i Lidingö.
Read more on company page